At a glance
- Nebulized VIP for 4 weeks reduced BAL TNF-α and expanded regulatory T cells in 20 sarcoidosis patients (Prasse et al. 2010).
- Inhaled 100 mcg VIP dropped mean pulmonary arterial pressure ~10 mmHg in 8 primary pulmonary hypertension patients (Petkov et al. 2003).
- Aviptadil (IV VIP) missed its primary endpoint in a 196-patient COVID-19 RCT but showed a 60-day survival signal (Youssef et al. 2022).
- VIP induces CD4+CD25+Foxp3+ regulatory T cells in mouse models of autoimmunity (Fernandez-Martin et al. 2006).
- Systemic half-life is ~2 minutes, which is why almost every research protocol uses intranasal or nebulized delivery.
Most VIP peptide "benefits" pages read like a supplement ad. The compound is real, the mechanisms are real, and there is genuine human trial data. That data is smaller and messier than the marketing suggests, and it is spread across four disease areas that almost never get discussed in the same article. This one puts them side by side and shows what changed, in whom, at what dose.
Vasoactive intestinal peptide is a 28-amino-acid endogenous neuropeptide first isolated from porcine duodenum by Sami Said and Viktor Mutt in 1970. It signals through two G-protein coupled receptors, VPAC1 and VPAC2, and its downstream effects touch the immune system, the pulmonary vasculature, gut motility, circadian rhythm, and the anterior pituitary. Fifty-plus years of research produced a picture that is fascinating in animal models and modest in humans. That gap is the whole story.
Bottom line: The best-controlled human VIP data comes from three studies: a 20-patient Phase II sarcoidosis trial with immunoregulatory effect, an 8-patient primary pulmonary hypertension pilot with hemodynamic improvement, and a 196-patient COVID-19 RCT that missed its primary endpoint. Everything else is preclinical, observational, or unpublished protocol experience.
What VIP actually is
VIP belongs to the secretin/glucagon peptide family and shares roughly 68% homology with PACAP, its closest structural cousin. The peptide is released from parasympathetic nerve terminals, enteric neurons, and immune cells. Circulating VIP has a half-life of only about two minutes (Delgado & Ganea 2013), which is why almost every clinical protocol delivers it locally, either as a nasal spray or as a nebulized aerosol, rather than as a systemic subcutaneous injection.
Signaling runs through VPAC1 and VPAC2, both G-protein coupled receptors that raise intracellular cAMP. Cell types that express these receptors include T lymphocytes, macrophages, dendritic cells, alveolar type II cells, pulmonary vascular smooth muscle, and enteric neurons. That receptor distribution is why VIP shows up in so many disease models: immunoregulatory in autoimmunity, vasodilatory in pulmonary hypertension, cytoprotective in acute lung injury, and pro-motility in the gut.
For dosing formats, delivery routes, and reconstitution notes, the VIP dosage chart walks through the intranasal protocol most research groups use, and the VIP compound page covers structure and storage.
The evidence hierarchy at a glance
| Benefit claim | Best available human evidence | Dose and route | Strength of evidence |
|---|---|---|---|
| Reduces pulmonary inflammation in sarcoidosis | Prasse et al. (2010), n = 20, open-label Phase II | 100 mcg nebulized, 4 times daily, 4 weeks | Small, uncontrolled, but published in AJRCCM |
| Lowers pulmonary arterial pressure in PAH | Petkov et al. (2003), n = 8, prospective intraindividual | 100 mcg inhaled, single-dose acute study | Small pilot, hemodynamic endpoint |
| Improves survival in critical COVID-19 respiratory failure | Youssef et al. (2022), n = 196, RCT | IV aviptadil, 3-day infusion, 2:1 vs placebo | Randomized but missed primary endpoint |
| Induces regulatory T cells | Fernandez-Martin et al. (2006), mouse EAE | 5 nmol IP daily | Preclinical, mechanistic |
| Broad anti-inflammatory / cytokine suppression | Delgado & Ganea (2013) review | Various | Mostly in vitro and rodent |
| "CIRS / mold" recovery (Shoemaker protocol) | Case series, non-randomized, largely unindexed | 50 mcg intranasal, 4x daily | Grey literature |
Two patterns come out of that table. First, the strongest human trials sit inside conventional respiratory and immune medicine, not the wellness-peptide space. Second, every well-designed study used inhaled or nebulized delivery. Subcutaneous VIP in humans has not been meaningfully tested.
Immunomodulation and regulatory T cells
VIP's most consistent preclinical finding is that it shifts adaptive immunity toward tolerance. In mice with experimental autoimmune encephalomyelitis (the standard multiple sclerosis model), daily IP VIP expanded the CD4+CD25+Foxp3+ regulatory T cell pool in the periphery and central nervous system and suppressed encephalitogenic T-cell activation (Fernandez-Martin et al., 2006). Parallel work in collagen-induced arthritis produced similar Treg induction with disease-modifying effect at the joint level.
The mechanism is a two-step handoff. VIP first acts on antigen-presenting cells, especially dendritic cells and macrophages, downregulating NF-κB signaling, inhibiting TNF-α, IL-6, IL-12, and nitric oxide production, and biasing dendritic cells toward a tolerogenic phenotype. Those tolerogenic DCs then prime naive CD4 T cells into functional Foxp3+ Tregs. The Delgado and Ganea review synthesizes 15 years of this work and lays out the receptor-level detail (Delgado & Ganea 2013).
The honest caveat here is that inducing Tregs in a mouse of autoimmune disease is different from inducing clinically meaningful Tregs in an outbred human with a chronic inflammatory condition. That translation has not been directly measured in a peptide-therapeutic trial outside sarcoidosis. For the broader set of immune-directed peptides that have made it to controlled trials, the best peptides for immune support hub and the thymosin alpha-1 clinical evidence article walk through the actual evidence base.
Sarcoidosis: the Prasse Phase II
Sarcoidosis is a granulomatous inflammatory disease of the lung driven by Th1 and Th17 responses. Antje Prasse and colleagues at the University of Freiburg ran an open-label Phase II trial in 20 patients with histologically confirmed active pulmonary sarcoidosis, giving nebulized VIP 100 mcg four times daily for four weeks. Every patient continued their existing therapy. Endpoints came from bronchoalveolar lavage before and after treatment.
The results were mechanistically clean. TNF-α production by BAL cells fell significantly. The proportion of CD4+CD25brightFoxp3+ regulatory T cells in BAL rose. Serum VIP levels stayed unchanged, consistent with local action in the lung rather than systemic exposure. Treatment was safe and well tolerated, with no drug-related serious adverse events (Prasse et al., 2010).
What the trial did not do is measure lung function change against a placebo group. It is a 20-person open-label study designed to test whether inhaled VIP moves immune biomarkers in the human lung in the direction its mouse data predicted. It did. That is a real result. It is not a proof of clinical efficacy, and the authors said so, calling for the multicenter controlled study that has still not been published sixteen years later.
Primary pulmonary hypertension: the Petkov pilot
Pulmonary arterial hypertension patients have measurably reduced VIP in serum and lung tissue, and their pulmonary arteries lose the VIP-containing nerve fibers that healthy vessels carry. Vlado Petkov and colleagues in Vienna tested whether replacing that missing VIP with a single inhaled dose changed pulmonary hemodynamics.
Eight PPH patients underwent right-heart catheterization at baseline. After a single inhalation of 100 mcg aerosolized VIP, mean pulmonary arterial pressure dropped by about 10 mmHg, cardiac output rose, and mixed venous oxygen saturation improved. There were no systemic hypotension events or other adverse effects reported (Petkov et al., 2003).
An acute hemodynamic response in eight patients is not a treatment. It is proof of the concept that inhaled VIP reaches functional receptors in the pulmonary vasculature at doses low enough not to drop systemic blood pressure. Larger studies of the analog aviptadil in pulmonary hypertension were pursued and did not reach approval, but the acute pilot remains the clearest example of a measured hemodynamic benefit from inhaled VIP in humans.
COVID-19 respiratory failure: the aviptadil RCT
Aviptadil is a synthetic form of human VIP that received FDA orphan drug designations for acute respiratory distress syndrome (2001) and pulmonary arterial hypertension (2005), long before COVID-19 existed. When the pandemic hit, the rationale was direct. VIP binds VPAC1 on alveolar type II cells, the same cells SARS-CoV-2 targets. Preclinical work showed it upregulated surfactant, inhibited cytokine synthesis, and blocked viral replication in cultured pulmonary cells.
Youssef and colleagues ran a multicenter placebo-controlled RCT in 196 patients with critical COVID-19 respiratory failure, randomized 2:1 to a three-day IV infusion of aviptadil versus placebo. The primary endpoint was survival with freedom from respiratory failure at day 60. That endpoint did not reach statistical significance. Secondary analyses reported a numerical survival benefit at day 60 across all sites of care, no drug-related serious adverse events, and an acceptable safety profile in a critically ill population (Youssef et al., 2022).
This is the kind of trial the peptide-benefits literature tends to misread. The aviptadil RCT is the largest published human VIP dataset in existence, and it missed its primary endpoint. That does not erase the safety data or the secondary signals, and it also does not turn the drug into a proven COVID therapy. It is a real result that says the effect, if it exists, is smaller than the trial was powered to detect.
The CIRS / mold protocol claim
Vasoactive intestinal peptide is best known outside conventional medicine through Ritchie Shoemaker's chronic inflammatory response syndrome (CIRS) protocol. Practitioners in that community report low VIP levels in patients with mold-related illness and use intranasal VIP, typically 50 mcg per spray up to four times daily, as a late-stage treatment after biotoxin removal.
The clinical claims include improvements in pulmonary artery pressure, exercise tolerance, cognition, and quality-of-life scores. The evidence for those claims is a Shoemaker case-series paper published in a low-visibility open-access journal in 2013, plus practitioner-reported outcomes. Neither is indexed as a controlled clinical trial. This does not mean the observations are fake. It means they have not been tested with a randomized comparator, blinded outcome assessment, or independent replication.
The honest way to think about the CIRS protocol is as an off-label practitioner tradition informed by real Shoemaker-era observations, not as a validated therapy. Anyone considering it for personal research use should read the Shoemaker publications directly and understand that the peptide-benefits marketing on vendor sites tends to elide the difference between "practitioner case series" and "clinical trial."
Delivery routes and dosing formats used in research
| Format | Typical research dose | Where it appears in the literature |
|---|---|---|
| Nebulized aerosol | 100 mcg four times daily | Prasse sarcoidosis Phase II |
| Inhaled single-dose aerosol | 100 mcg once, acute testing | Petkov PAH pilot |
| Intravenous continuous infusion | Weight-based, 3-day course (aviptadil) | Youssef COVID-19 RCT |
| Intranasal spray | 50 mcg per actuation, up to 4x/day | Shoemaker CIRS protocol, unindexed |
| Subcutaneous injection | Not used in published human trials | Absent |
The pattern is not accidental. Native VIP is degraded in seconds by circulating peptidases, so bolus subcutaneous dosing produces very low tissue exposure. Nebulization and nasal delivery bypass that problem by placing the peptide directly at the target tissue. The intranasal 50 mcg protocol emerged from CIRS practitioner experience because pumping 50 mcg into the sinus once or four times a day is more practical than nebulizing 100 mcg four times a day.
For a full comparison of intranasal dosing schedules and reconstitution steps, the VIP dosage chart covers the standard 50 mcg intranasal protocol, the conservative entry ladder, and the maintenance approach. Sourcing matters here too. Because bioactivity depends on peptide integrity and because intranasal delivery skips first-pass metabolism, contaminants or degraded peptide land directly on mucosal tissue. The Ascension Peptides review walks through what a real per-lot COA looks like, and the lab-tests library catalogs the peptide-purity data behind that.
Safety
Across the published human studies, VIP has been well tolerated. The Prasse trial reported no drug-related serious adverse events in four weeks of nebulized dosing. Petkov reported no systemic hypotension in the acute PAH pilot despite VIP being a potent vasodilator. The aviptadil RCT reported an acceptable safety profile in critically ill patients.
Expected on-target effects include flushing, mild transient hypotension, and headache, all consistent with cAMP-mediated vasodilation. The intranasal route can cause local irritation. VIP is a research compound, not an approved therapeutic for any indication outside of aviptadil's orphan designations, and no long-term safety data exists in healthy volunteers.
Tip: Because VIP is a potent vasodilator, protocols generally start with a single 50 mcg intranasal actuation and observe blood pressure and flushing for at least a week before increasing frequency. This is the same conservative pattern used in early Shoemaker practitioner protocols.
What the human data does not support
A cleaner answer than "VIP boosts your immune system" is a list of things the human trials did not show:
- No randomized controlled trial has demonstrated that VIP improves clinical outcomes in a general immune-support setting.
- No trial has shown that intranasal VIP produces measurable Treg expansion in healthy subjects.
- No trial has tested subcutaneous VIP in humans for any indication.
- The COVID-19 RCT of aviptadil, the largest human VIP dataset available, missed its primary endpoint.
- The CIRS protocol has not been tested against placebo in a randomized design.
None of that makes VIP an uninteresting molecule. It makes it a research compound with real mechanistic data, a handful of small human trials with mechanistic wins, and one large trial that failed its endpoint. The compound is worth studying. The marketing is worth ignoring.
How VIP compares to other immune-directed peptides
Within the immune-modulating peptide category, VIP occupies a specific niche. It is the strongest vasodilator of the group and the only one with published human hemodynamic data. It is not the strongest evidence base. Thymosin alpha-1 has decades of clinical trials in chronic hepatitis and adjunctive vaccine response. KPV, the α-MSH tripeptide, has cleaner oral bioavailability. LL-37 sits in the antimicrobial peptide category with a different mechanism entirely. The peptides for inflammation overview compares the mechanisms and evidence side by side.
If your research question is anti-inflammatory Treg induction with pulmonary tropism, VIP is the peptide with the best mechanistic case. If your question is broad-spectrum immune modulation with the strongest clinical evidence base, thymosin alpha-1 has more data. If your question is oral gut inflammation, KPV was designed for it. The compounds are not interchangeable.
Bottom line: VIP is one of the most mechanistically interesting peptides in the immune-modulator category and one of the most oversold in the direct-to-consumer market. Its best human evidence is small, local, and disease-specific. Anyone using it for research should match protocol to that evidence, not to marketing copy.
Research sourcing
For research applications, sourcing is not optional. VIP is fragile, degrades quickly, and lands directly on mucosal tissue via intranasal delivery. Verified purity matters more here than for most peptides. Ascension Peptides carries a research VIP vial with published purity data. The full breakdown, including code ENHANCED for 50% off injectable research peptides, is in the Ascension Peptides review. Whichever vendor you evaluate, insist on a per-lot certificate of analysis rather than a generic spec sheet.
This article is for research and educational purposes only. It is not medical advice, and it does not recommend the use of vasoactive intestinal peptide or aviptadil for any clinical condition. All human trials cited were conducted under formal clinical research protocols with regulatory oversight. Nothing described here should be interpreted as a treatment recommendation.
